Browse > Article

The Clinical Value of Dual Time Point F-18 FDG PET/CT Imaging for the Differentiation of Colonic Focal Uptake Lesions  

Kim, Jin-Suk (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital)
Lim, Seok-Tae (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital)
Jeong, Young-Jin (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital)
Kim, Dong-Wook (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital)
Jeong, Hwan-Jeong (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital)
Sohn, Myung-Hee (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital)
Publication Information
Nuclear Medicine and Molecular Imaging / v.43, no.4, 2009 , pp. 309-316 More about this Journal
Abstract
Purpose: F-18 FDG can be accumulated in the liver, bowel, kidney, urinary tract, and muscles physiologically. The aim of this study was to evaluate the clinical value of dual time point 18F-FDG PET /8 imaging for the differentiation of the colonic focal uptake lesions. Materials and Methods: One hundred thirty two patients (M:F = 77:55, Age 62.8$\pm$11.6 years) underwent $^{18}$F-FDG PET/CT at two time points, prospectively: early image at 50-60 min and delayed image at 4-4.5 hours after the intravenous injection of $^{18}$F-FDG. Focally increased uptake lesions on early images but disappeared or shifted on delayed images defined a physiological uptake. For the differential evaluation of persistent focal uptake lesions on delayed images, colonoscopy and histopathologic examination were performed. SUVmax changes between early and delayed images were also compared. Results: Among the 132 patients, 153 lesions of focal colonic uptake were detected on early images of $^{18}$F-FDG PET/CT. Of these, 72 (47.1%) lesions were able to judge with physiological uptake because the focal increased uptake disappeared from delayed image. Among 81 lesions which was showed persistent increased uptake in delayed image, 61 (75.3%) lesions were confirmed as the malignant tumor and 14 (17.3%) lesions were confirmed as the benign lesions including adenoma and inflammatory disease. Remaining 6 (7.4%) lesions were confirmed as the physiological uptake because there was no particular lesion in the colonoscopy. In the malignant lesions, the calculated dual time point change for SUVmax ($\Delta$%SUVmax) was 20.8$\pm$18.7%, indicating a significant increase in SUVmax between the two point (p<0.01). In contrast, the change in SUVmax for the non-malignant lesions including benign lesions and physiological uptake was -13.7%$\pm$24.2%. For the differentiation of the malignant and non-malignant focal colonic uptake lesions, $\Delta$%SUVmax was the most effective parameter, and the cut-off value using -5% provided the best sensitivity, specificity, and accuracy. Conclusion: The dual time point $^{18}$F-FDG PET/CT imaging with SUVmax change evaluation could be an important noninvasive method for the differentiation of malignant and benign focal colonic uptake lesions including physiologic uptake.
Keywords
Dual time point; $^{18}$F-FDG; PET/CT; colonic focal uptake lesion;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Prabhakar HB, Sahani DV, Fischman AJ, Mueller PR, Blake MA. Bowel hot spots at PET-CT. Radioreaphics 2007;27:145-59   DOI   ScienceOn
2 Israel O, Yefremov N, Bar-Shalom R, Kaqana O, Frenkel A. PET/CT detection of unexpected gastrointestinal foci of $^{18}$F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med 2005;46:758-62   PUBMED   ScienceOn
3 Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Tsutsui K, Wakabayashi H, et al. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl Med Commun 2005;26:895-901   DOI   ScienceOn
4 Kim S, Chung JK, Kim BT, Kim SJ, Jeong JM, Lee DS, et al. Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in whole-body PET. Clin Posit Imaging 1999;2:273-80   DOI   ScienceOn
5 Hashimoto Y, Tsujikawa T, Kondo C, Maki M, Nagai A, Ohnuki T, et al. Accuracy of PET for diagnosis of solid pulmonary lesions with $^{18}$F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med 2006;47:426-31   PUBMED   ScienceOn
6 Lan XL, Zhang YX, Wu ZJ, Jia Q, Wei H. The value of dual time point $^{18}$F-FDG PET imaging for the differentiation between malignant and benign lesions. Clin Radiol 2008;63:756-64   DOI   ScienceOn
7 Thie JA. Optimizing dual-time and serial positron emission tomography and single photon emission computed tomography scans for diagnoses and therapy monitoring. Mol Imaging Biol 2007;9:348-56   DOI   ScienceOn
8 Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-74   DOI   ScienceOn
9 Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 2002;224:783-7   DOI   ScienceOn
10 Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed $^{18}$F -fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;89:2547-54   DOI   ScienceOn
11 Nishivama Y, Yamamoto Y, Fukunaqa K, Kimura N, Miki A, Sasakawa Y. Dual-time-point $^{18}$F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med 2006;47:633-8   PUBMED   ScienceOn
12 Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AT. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994;35:1308-12   PUBMED   ScienceOn
13 Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point $^{18}$F -FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871-5   PUBMED   ScienceOn
14 Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual time-point imaging to improve breast cancer diagnosis with $^{18}$F -FDG PET. J Nucl Med 2005;46:1819-24   ScienceOn
15 Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentineinduced inflammatory tissue. J Nucl Med 1995;36:1301-6   PUBMED   ScienceOn
16 Liang Y-C, Tang A-W, Xu H. Diagnostic value of $^{18}$F-FDG PET delayed imaging for patients with primary lung cancer. Chin J Nucl Med 2004;24:27-9
17 Hubner KF, Buonocore E, Gould HR, Thie J, Smith GT, Stephens S, et al. Differentiating benign from malignant lung lesions using “quantitative” parameters of FDG PETimages. Chin J Nucl Med 1996;21:941-9   PUBMED
18 Rohren EM, Turking TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-32   DOI   ScienceOn
19 Zhuang H, Pourdehnad M, Lambright ES, Yammoto AJ, Lanuti M, Mozley PD, et al. Dual time point $^{18}$F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412-7   PUBMED   ScienceOn
20 Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA. A PET study $^{18}$F-FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22-30   DOI   ScienceOn
21 Demura Y, Tsuchida T, Ishizaki T, Mizuno S, Totani Y, Ameshima S, et al. $^{18}F$-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003;44:540-8   PUBMED   ScienceOn
22 Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999;19:61-77   DOI   PUBMED   ScienceOn
23 Jarritt PH, Carson KJ, Hounsell AR, Visvikis D. The role of PET/CT scanning in radiotherapy planning. Br J Radiol 2006;79:S27-35   DOI   ScienceOn